A Multi-Center Cross-Sectional Study of the Status of Patient-Oriented Chinese Medicine Treatment of Malignant Tumors
Zi-Hua Yang （ Department of oncology, Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, Gansu, China ）
https://doi.org/10.37155/2717-5278-0101-3Abstract
Objective: To clarify the current status of traditional Chinese medicine (TCM) application and research in the field of tumor treatment, and provide reference guidance for the rational application of TCM in the treatment of tumors, multidisciplinary cooperation in tumor treatment, and improvement of TCM education. Methods: From July 2015 to June 2016, the patients in oncology department of four large-scale comprehensive first-class hospitals in China were selected. The general clinical data, clinical application of TCM and cognitive status data of tumor patients were obtained by using electronic medical record database combined with questionnaire to explore the clinical application of TCM in tumor treatment from the perspective of tumor patients. Results: The proportion of patients receiving chemotherapy (including targeted therapy) and TCM treatment was 28.7%. 16.6% of doctors were concerned that TCM combined with chemotherapy might produce adverse reactions. 20.0% of doctors think they have enough knowledge to answer questions related to TCM. 22.0% of doctors have received continuing education in TCM. During the treatment, 36.5% of patients had discussed TCM with their doctors. A total of 44.9% of doctors believe that TCM treatment is effective. Conclusion: The purpose of applying TCM is mainly to regulate the body’s immunity, improve the symptoms such as loss of appetite, fatigue and sleep disorder, increase the effect and reduce toxicity of radiotherapy and chemotherapy. The treatment is mainly based on TCM compounds and proprietary Chinese medicines.
Keywords
TCM; malignant tumor; clinical application; literature quality evaluationFull Text
PDFReferences
[2]Peng X, Zhao Y, Liang X, Wu L, Cui S, Guo A, Wang, W. Assessing the quality of RCTs on the effect of β-elemene, one ingredient of a Chinese herb, against malignant tumors. Contemp Clin Trials 2006,27(1),70-82.
[3]Liu Z, Chen S, Cai J, Zhang E, Lan L, Zheng J, Liao L, Yang X, Zhou C, Du J. Traditional Chinese medicine syndrome-related herbal prescriptions in treatment of malignant tumors. J Tradit Chin Med 2013,33(1),19-26.
[4]Lu Y, Xuan M, Takata T, Wang C, He Z, Zhou Z, Mock D, Nikai H. Odontogenic tumors: a demographic study of 759 cases in a Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998,86(6),707-714.
[5]Wang D, Li Y, He H, Liu L, Wu L, He Z. Intraoral minor salivary gland tumors in a Chinese population: a retrospective study on 737 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007,104(1),94-100.
[6]Li-Weber, M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett 2013,332(2),304-312.
[7]Chi Y, Zhan XK, Yu H, Xie GR, Wang ZZ, Xiao W, Wang YG, Xiong FX, Hu JF, Yang L, Cui CX, Wang JW. An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chin Med J 2013,126(9),1642-1646.
[8]Yu L, Ma R, Wang Y, Nishino H. Potent anti-tumor activity and low toxicity of tubeimoside 1 isolated from Bolbostemma paniculatum. Planta Med 1994,60(03),204-208.
[9]Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 2010,16(4),368-377.
[10]Kishikawa T, Numaguchi Y, Watanabe K, Matsuura K. Angiographic diagnosis of benign and malignant splenic tumors. AJR Am J Roentgenol 1978,130(2),339-344.
[11]Belamaric, J. Malignant tumors in chinese a report based on biopsy and autopsy material from chinese in hong kong. Int J Cancer 1969,4(4),560-573.
Copyright © 2019 Zi-Hua Yang
Publishing time:2019-12-31
This work is licensed under a Creative Commons Attribution 4.0 International License
Email
Location